Brett Hauber, PhD

Senior Economist and VP, Health Preference Assessment

PhD, Economics
MA, Economics
University of Delaware, Newark, DE

Temple University, Philadelphia, PA

Brett Hauber, PhD, is a Senior Economist and the Vice President of Health Preference Assessment at RTI-HS and an Affiliate Associate Professor in the School of Pharmacy at the University of Washington. He has more than 20 years of academic, research, and government experience in health and environmental economics. His primary area of specialization is in conducting stated-preference studies to quantify preferences for medical interventions and health outcomes. Dr. Hauber regularly teaches courses on stated-preference methods, discrete-choice experiments, and benefit-risk assessment. He was a member of to the Patient-Centered Benefit-Risk Steering Committee of the Medical Device Innovation Consortium (MDIC) and was the principal investigator for developing the Catalog of Methods for Assessing Patient Preferences for Benefits and Harms of Medical Technologies for MDIC. He has previously served as chair of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conjoint Analysis–Statistical Analysis, Reporting, and Conclusions (CA-SARC) task force and was a member of the ISPOR task force that developed the ISPOR Checklist for Good Research Practices in Conjoint Analysis.

Dr. Hauber is currently the Principal Investigator for the What Matters Most Study sponsored by AD PACE, a patient- and caregiver-led collaboration of industry, academics, and government agencies. He was recently the lead investigator an MDIC-sponsored study to elicit patient preferences for benefits and risks of medical devices to treatment Parkinson’s disease. The Parkinson’s preference study was the result of a collaborative effort by MDIC, the Center for Devices and Radiological Health of the FDA, The Michael J Fox Foundation for Parkinson’s Research, and the Massachusetts Institute of Technology to develop a patient-centered design for clinical trials of devices to treat Parkinson’s disease.

Dr. Hauber is currently a member of the scientific advisory board for the IMI-PREFER project and an advisor to a number of initiatives led by industry and patient-advocacy organizations to incorporate patient preferences in regulatory and reimbursement decision making in multiple disease areas. Dr. Hauber has been an invited speaker at multiple industry- and FDA-sponsored meetings. His research has been published in numerous health outcomes and medical journals.